



115

GAU 1625

RECEIVED

APR 05 2001

TECH CENTER 1600/2900

SOCKET NO.: CELL-0072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:  
Porter et al.

Serial No.: 09/326,020

Group Art Unit: 1625

Filing Date: June 4, 1999

Examiner: B. Robinson

For: PHENYLALANINE DERIVATIVES


DATE OF DEPOSIT: March 29, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS  
ADDRESSED TO THE ASSISTANT COMMISSIONER  
FOR PATENTS, WASHINGTON, DC 20231.

04/03/2001 SHINASS1 00000060 09326020

01 FC:115

110.00 OP

  
\_\_\_\_\_  
Gregory L. Hillyer  
REGISTRATION NO.: 44,154

Assistant Commissioner for Patents  
Washington DC 20231

Sir:

AMENDMENT TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified patent application is:

- ☐ A Preliminary Amendment.
- ☒ An Amendment Responsive to the Office Action Dated January 29, 2001.
- ☐ An Amendment Supplemental to the Paper filed \_\_\_\_\_.
- ☐ Other: \_\_\_\_\_.
- ☐ Small entity status of this application under 37 C.F.R. 1.9 and 1.27 was established in a previous submission.
- ☐ A Statement Claiming Small Entity Status under 37 C.F.R. 1.9 and 1.27 is enclosed.

- ☐ This application is no longer entitled to small entity status. It is requested that this be noted in the files of the Patent and Trademark Office.
- ☐ Substitute Pages \_\_\_\_\_ of the Specification are enclosed.
- ☐ An Abstract is enclosed.
- ☐ \_\_\_\_\_ Sheets of Proposed Corrected Drawings are enclosed.
- ☐ A Certified Copy of each of the following applications: \_\_\_\_\_  
\_\_\_\_\_ is enclosed.
- ☐ An Associate Power of Attorney is enclosed.
- ☐ Information Disclosure Statement.
- ☐ Attached Form 1449.
- ☐ A copy of each reference as listed on the attached Form PTO-1449 is enclosed herewith.
- ☐ Appended Material as follows: \_\_\_\_\_ .
- ☐ Other Material as follows: \_\_\_\_\_ .

## FEE CALCULATION

☐ No Additional Fee is Due.

	REMAINING AFTER AMENDMENT	HIGHEST PAID FOR	EXTRA	SMALL ENTITY		NOT SMALL ENTITY	
				RATE	FEE	RATE	FEE
TOTAL CLAIMS	19	20 (20 MINIMUM)	0	\$9 EACH	\$	\$18 EACH	\$
INDEP. CLAIMS	3	3 (3 MINIMUM)	0	\$39 EACH	\$	\$78 EACH	\$
FIRST PRESENTATION OF MULTIPLE DEPENDENT				\$130	\$	\$260	\$
<input checked="" type="checkbox"/> ONE MONTH EXTENSION OF TIME				\$55	\$	\$110	\$110.00
<input type="checkbox"/> TWO MONTH EXTENSION OF TIME				\$190	\$	\$380	\$
<input type="checkbox"/> THREE MONTH EXTENSION OF TIME				\$435	\$	\$870	\$
<input type="checkbox"/> FOUR MONTH EXTENSION OF TIME				\$680	\$	\$1360	\$
<input type="checkbox"/> FIVE MONTH EXTENSION OF TIME				\$925	\$	\$1850	\$
<input type="checkbox"/> LESS ANY EXTENSION FEE ALREADY PAID				minus	(\$ )	minus	(\$ )
<input type="checkbox"/> TERMINAL DISCLAIMER				\$55	\$	\$110	\$
<input type="checkbox"/> OTHER FEE OR SURCHARGE AS FOLLOWS:							
TOTAL FEE DUE							\$110.00

- ☒ A Check is Enclosed in the Foregoing Amount Due.
- ☒ Petition is hereby made under 37 C.F.R. 1.136(a) to extend the time for response to the Office Action of **January 29, 2001** to and through **March 29, 2001** comprising an extension of the shortened statutory period of 1 month(s).
- ☒ The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-

identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

- ☒ The Commissioner is authorized to charge payment of the following fees and to refund any overpayment associated with this communication or during the pendency of this application to deposit account 23-3050. This sheet is provided in duplicate.
- ☐ The Foregoing Amount Due for Filing this Paper.
- ☒ Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.
- ☒ Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).

**SHOULD ANY DEFICIENCIES APPEAR** with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: March 29, 2001



Gregory L. Hillyer  
Registration No. 44,154

Woodcock Washburn Kurtz  
Mackiewicz & Norris LLP  
One Liberty Place - 46th Floor  
Philadelphia PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



DOCKET NO.: CELL-0072

PATENT

RECEIVED

APR 05 2001

TECH CENTER 1600/2900

#23  
pg 45/101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

**John Robert Porter, John Clifford Head,  
Graham John Warrellow, and Sarah Catherine Archibald**

Serial No.: 09/326,020

Group Art Unit: 1625

Filed: June 4, 1999

Examiner: B. Robinson

For: **PHENYLALANINE DERIVATIVES**

I, Gregory L. Hillyer, Registration No. 44,154 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

On March 29, 2000

  
Gregory L. Hillyer, Reg. No. 44,154

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**REPLY UNDER 37 C.F.R. § 1.146 TO  
OFFICE ACTION DATED JANUARY 29, 2001**

This is in response to the Requirement For Restriction mailed on January 29, 2001.

A restriction has been required to one of three groups of inventions, classified as Groups I, II, and III. Group I (claims 1-19) is drawn to a compound of formula (Ia) wherein R<sup>1</sup> is an optionally substituted phenyl, a method of treating diseases comprising administering a compound of formula (Ia) wherein R<sup>1</sup> is an optionally substituted phenyl, a method of inhibiting

an  $\alpha 4\beta 7$  integrin binding to ligands comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted phenyl, and pharmaceutical compositions comprising a compound of formula (Ia) wherein  $R^1$  is an optionally substituted phenyl. Group II (claims 1-19) is drawn to a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl, a method of treating diseases comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl, a method of inhibiting an  $\alpha 4\beta 7$  integrin binding to ligands comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl, and pharmaceutical compositions comprising a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl. Group III (claims 1-19) is drawn to a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyrimidinyl, a method of treating diseases comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyrimidinyl, a method of inhibiting an  $\alpha 4\beta 7$  integrin binding to ligands comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyrimidinyl, and pharmaceutical compositions comprising a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyrimidinyl.

It is asserted in the Office Action that Groups I, II, and III are unrelated in that they have different modes of operation, different functions, or different effects. Specifically, the Office Action contends that the "different inventions" can be used as inhibitors of beta amyloid protein production or as protease inhibitors. The mere fact, however, that certain phenylalanine derivatives may inhibit beta amyloid protein production or protease, does not mean that these

derivatives have different modes of operation, functions, or effects *in the disclosed invention*.

Thus, it is submitted respectfully that the restriction requirement is deficient in that a showing has not been made that the involved claims are directed to independent inventions.<sup>1</sup> Inventions are only deemed "independent" if there is no disclosed relationship and/or if the inventions are unconnected in design, operation or effect. *See* M.P.E.P. §802.01. Applicants, however, *have* disclosed a common relationship involving, *inter alia*, inhibition of  $\alpha 4\beta 7$  integrin by compounds having a common phenylalanine core. This common relationship establishes that the subject matter is not misjoined as the Office Action suggests.

The purpose of § 121 is to avoid a situation which requires that separate and diverse searches be conducted on claims directed to independent (unrelated) subject matter. That is not the situation here because the relationship among the compounds of formula (Ia) is such that a reasonable search for phenylalanine derivatives generally would necessarily lead to disclosures, to the extent any exist, of compounds wherein R<sup>1</sup> is either an optionally substituted phenyl, pyridyl, or pyrimidinyl. Accordingly, Applicants submit respectfully that it is incumbent upon the Examiner to conduct such a search.

Applicants hereby elect for prosecution Group II (claims 1-19), which is drawn to a compound of formula (Ia) wherein R<sup>1</sup> is an optionally substituted pyridyl, a method of treating diseases comprising administering a compound of formula (Ia) wherein R<sup>1</sup> is an optionally

---

<sup>1</sup> 35 U.S.C. §121 states that an application can be restricted if two or more inventions are, *inter alia*, independent.

substituted pyridyl, a method of inhibiting an  $\alpha 4\beta 7$  integrin binding to ligands comprising administering a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl, and pharmaceutical compositions comprising a compound of formula (Ia) wherein  $R^1$  is an optionally substituted pyridyl, with traverse. Applicants hereby affirm the right to file one or more divisional applications with respect to any of the non-elected subject matter.

**Conclusion**

Applicant believes that the foregoing constitutes a complete and full response to the Office Action of record. Accordingly, an early and favorable action on the merits is requested respectfully.

Respectfully submitted,



Gregory L. Hillyer  
Registration No. 44,154

Date: March 29, 2001  
WOODCOCK WASHBURN KURTZ  
MACKIEWICZ & NORRIS LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
(215) 568-3100